<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04256174</url>
  </required_header>
  <id_info>
    <org_study_id>AK120-101</org_study_id>
    <nct_id>NCT04256174</nct_id>
  </id_info>
  <brief_title>A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis</brief_title>
  <official_title>A Phase 1, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AK120 in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akesobio Australia Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akeso</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A dose escalation, first-in-human study evaluating the safety, tolerability,&#xD;
      pharmacokinetics, pharmacodynamics and immunogenicity of AK120 in healthy subjects and&#xD;
      subjects with moderate- to- severe atopic dermatitis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1, randomized, two-part, double-blind, placebo-controlled, dose-escalation,&#xD;
      first-in-human study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics&#xD;
      and immunogenicity of AK120 in healthy subjects (part 1, single ascending dose) and subjects&#xD;
      with moderate- to- severe atopic dermatitis(part 2, multiple ascending dose)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2020</start_date>
  <completion_date type="Anticipated">July 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 19, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events(AEs)/serious adverse events(SAEs)</measure>
    <time_frame>From signing of informed consent through through 12 weeks post-dose</time_frame>
    <description>Incidence of treatment emergent adverse events(AEs)/serious adverse events(SAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thymus and activation regulated chemokine (TARC)/Chemokine Ligand 17(CCL17)</measure>
    <time_frame>From baseline through 12 weeks post-dose</time_frame>
    <description>Change from baseline in serum levels of thymus activation and regulated chemokine (TARC)/Chemokine Ligand 17 (CCL17) in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax)</measure>
    <time_frame>From baseline through 12 weeks post-dose</time_frame>
    <description>Maximum observed serum concentration (Cmax) of AK120</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC)</measure>
    <time_frame>From baseline through 12 weeks postdose</time_frame>
    <description>Area under the concentration-time curve (AUC) of serum concentration of AK120</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibodies(ADAs)</measure>
    <time_frame>From baseline through 12 weeks postdose</time_frame>
    <description>Number and percentage of subjects who develop detectable anti-drug antibodies(ADAs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator global assessment (IGA) (part 2)</measure>
    <time_frame>From baseline through 12 weeks postdose</time_frame>
    <description>The proportion of subjects with Investigator global assessment (IGA) 0 to 1 and subjects with IGA reduction from baseline of ≥ 2-point.&#xD;
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a static 6-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe；5 = very severe) based on erythema and papulation/infiltration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritus-Numeric Rating Scale (P-NRS) (part 2)</measure>
    <time_frame>From baseline through 12 weeks postdose</time_frame>
    <description>The proportion of subjects with Pruritus-Numeric Rating Scale (P-NRS) improvement (reduction) from baseline of ≥ 3-point.&#xD;
Pruritus NRS is an assessment tool that is used to report the intensity of participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Eczema Area and Severity Index (EASI) score(part 2)</measure>
    <time_frame>From baseline through 12 weeks postdose</time_frame>
    <description>The EASI score was used to measure the severity and extent of atopic dermatitis (AD). The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body surface area (BSA) of AD involvement. (part 2)</measure>
    <time_frame>From baseline through 12 weeks postdose</time_frame>
    <description>Body surface area determined by palm method where 1 palm is equivalent to 1%. Total body surface area ranges from 1% to 100%, with the higher body surface area reflecting the worse severity of AD.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Part 1:15mg cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 15mg AK120 or placebo is administered subcutaneously to healthy subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: 50mg cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 50mg AK120 or placebo is administered subcutaneously to healthy subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: 150mg cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 150mg AK120 or placebo is administered subcutaneously to healthy subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: 300 mg cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 300mg AK120 or placebo is administered subcutaneously to healthy subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: 600 mg cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 600mg AK120 or placebo is administered subcutaneously to healthy subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: low dose cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple low doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: medium dose cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple medium doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: high dose cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple high doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK120 or placebo- Part 1- Cohort 1</intervention_name>
    <description>Single dose of 15mg AK120 or placebo is administered subcutaneously to healthy subjects</description>
    <arm_group_label>Part 1:15mg cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK120 or placebo- Part 1- Cohort 2</intervention_name>
    <description>Single dose of 50mg AK120 or placebo is administered subcutaneously to healthy subjects</description>
    <arm_group_label>Part 1: 50mg cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK120 or placebo- Part 1- Cohort 3</intervention_name>
    <description>Single dose of 150mg AK120 or placebo is administered subcutaneously to healthy subjects</description>
    <arm_group_label>Part 1: 150mg cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK120 or placebo- Part 1- Cohort 4</intervention_name>
    <description>Single dose of 300mg AK120 or placebo is administered subcutaneously to healthy subjects</description>
    <arm_group_label>Part 1: 300 mg cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK120 or placebo- Part 1- Cohort 5</intervention_name>
    <description>Single dose of 600mg AK120 or placebo is administered subcutaneously to healthy subjects</description>
    <arm_group_label>Part 1: 600 mg cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK120 or placebo- Part 2- Cohort 1</intervention_name>
    <description>Multiple low doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis</description>
    <arm_group_label>Part 2: low dose cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK120 or placebo- Part 2- Cohort 2</intervention_name>
    <description>Multiple medium doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis</description>
    <arm_group_label>Part 2: medium dose cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK120 or placebo- Part 2- Cohort 3</intervention_name>
    <description>Multiple high doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis</description>
    <arm_group_label>Part 2: high dose cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet all the following inclusion criteria (as applicable) to be eligible for&#xD;
        participation in this study:&#xD;
&#xD;
        Part 1:&#xD;
&#xD;
          1. Willing and able to understand and sign an Informed Consent Form (ICF).&#xD;
&#xD;
          2. Women or men between 18 and 55 years of age, inclusive, at screening.&#xD;
&#xD;
          3. Must have a calculated body mass index within 18.0 to 30.0 kg/m2 (inclusive) at&#xD;
             screening, and a total body weight ≥50 kg for men or ≥45 kg for women at screening and&#xD;
             Day -1 before randomization.&#xD;
&#xD;
          4. Women of childbearing potential who are sexually active must use one of the permitted&#xD;
             methods of contraception from screening until at least 180 days after dosing of study&#xD;
             medication.&#xD;
&#xD;
          5. Non-sterilized male subjects who are sexually active with a female partner of&#xD;
             childbearing potential must use an effective method of contraception from Day 1&#xD;
             through 180 days after dosing of study medication.&#xD;
&#xD;
          6. Must, in the opinion of the Investigator, be in good general health based upon medical&#xD;
             history, physical examination (including vital signs), and 12-lead ECG; and clinical&#xD;
             laboratory tests&#xD;
&#xD;
        Part 2:&#xD;
&#xD;
          1. Male or female, aged 18 to 65 years (inclusive) at time of Screening.&#xD;
&#xD;
          2. Chronic atopic dermatitis (AD) diagnosed by the revised Hanifin and Rajka criteria&#xD;
             that has been present for at least 1 year before the Screening visit.&#xD;
&#xD;
          3. EASI score ≥12 at the screening and baseline visits.&#xD;
&#xD;
          4. IGA score ≥3 at the screening and baseline visits.&#xD;
&#xD;
          5. BSA of AD involvement ≥10% at the screening and baseline visits.&#xD;
&#xD;
          6. History of an inadequate response or medically inappropriate use of topical drug&#xD;
             treatment, in the judgment of the Investigator, to AD treatment with a topical regimen&#xD;
             of corticosteroids, phosphodiesterase inhibitors or calcineurin inhibitors or with&#xD;
             phototherapy within 6 months of the Screening visit.&#xD;
&#xD;
          7. Subjects must be applying stable doses of an additive-free, basic bland emollient&#xD;
             twice daily for at least 7 days before the baseline visit.&#xD;
&#xD;
        Major Exclusion Criteria:&#xD;
&#xD;
        Subjects who meet any of the following exclusion criteria will not be enrolled in this&#xD;
        study:&#xD;
&#xD;
        Part 1:&#xD;
&#xD;
          1. Clinically significant clinical safety laboratory result, or blood pressure or&#xD;
             electrocardiogram (ECG) abnormalities.&#xD;
&#xD;
          2. Current acute infection or history of acute infection within 7 days prior to receipt&#xD;
             of the study drug.&#xD;
&#xD;
          3. Have a recent history of conjunctivitis or keratitis within 6 months prior to&#xD;
             screening.&#xD;
&#xD;
          4. History or complications of tuberculosis, or evidence of latent tuberculosis by&#xD;
             QuantiFERON®-TB Gold screening.&#xD;
&#xD;
          5. Are positive for hepatitis B surface antigen, hepatitis C antibodies, or human&#xD;
             immunodeficiency virus (HIV) at screening.&#xD;
&#xD;
        Part 2:&#xD;
&#xD;
          1. The washout period for prior drug therapy (eg. corticosteroids,&#xD;
             immunosuppressive/immunomodulating, biologics, phototherapy, Chinese&#xD;
             medicine，anti-infective agents) is inadequate.&#xD;
&#xD;
          2. Any medical or psychiatric condition, laboratory or ECG parameter which, in the&#xD;
             opinion of the Investigator or the Sponsor's medical monitor, would place the subject&#xD;
             at risk, interfere with participation in the study, or interfere with the&#xD;
             interpretation of study results.&#xD;
&#xD;
          3. History of exposure to active TB, and/or history or current evidence of TB infection;&#xD;
             and/or Chest X-ray showed old TB lesions at Screening or within 3 months before the&#xD;
             Screening visit ..&#xD;
&#xD;
          4. Positive results at Screening for hepatitis B surface antigen (HBsAg), hepatitis B&#xD;
             core antibody (HBcAb) or hepatitis C antibody with positive hepatitis C virus (HCV)&#xD;
             RNA polymerase chain reaction; positive HIV serology at screening.&#xD;
&#xD;
          5. Any history of vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC)&#xD;
             within 6 months before the baseline visit.&#xD;
&#xD;
          6. History of clinical parasite infection, recent or planned travel to an area with&#xD;
             endemic parasite infection within 6 months before the Screening visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Miao Wang</last_name>
    <phone>+86 (0760) 8987 3999</phone>
    <email>global.trials@akesobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CMAX Clinical Research</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Victoria Ingleson</last_name>
      <phone>+618 7088 7948</phone>
      <email>Victoria.ingleson@cmax.com.au</email>
    </contact>
    <investigator>
      <last_name>Catherine Reid</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sinclair Dermatology</name>
      <address>
        <city>East Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stacy Jones</last_name>
      <phone>+613 9013 0099.</phone>
      <email>Stacy.Jones@sinclairdermatology.com.au</email>
    </contact>
    <investigator>
      <last_name>Rodney Sinclair</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peninsula Specialist Centre</name>
      <address>
        <city>Kippa-Ring</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maryanne Ryan</last_name>
      <phone>+617 3889 5577</phone>
      <email>maryanne@houston.net.au</email>
    </contact>
    <investigator>
      <last_name>Anthony Houston</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scientia Clinical Research Ltd</name>
      <address>
        <city>Randwick</city>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Hynes</last_name>
      <phone>+61 2 9382 5898</phone>
    </contact>
    <investigator>
      <last_name>Charlotte Lemech</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Clinical Trials - Waitemata</name>
      <address>
        <city>Birkenhead</city>
        <state>Auckland</state>
        <zip>0626</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicklas Gemmell</last_name>
      <phone>+64 9973 5927</phone>
      <email>niklas@sctrials.co.nz</email>
    </contact>
    <investigator>
      <last_name>Susan Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Optimal Clinical Trials</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Canepari</last_name>
      <phone>+64 9303 4987</phone>
      <email>elena@optimalclinicaltrials.com</email>
    </contact>
    <investigator>
      <last_name>Penelope Montgomery Montgomery</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christchurch Clinical Studies Trust</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southern Clinical Trials - Christchurch</name>
      <address>
        <city>Christchurch</city>
        <zip>8013</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tania De la Cruz</last_name>
      <phone>+64 3337 1979</phone>
      <email>tania@sctrials.co.nz</email>
    </contact>
    <investigator>
      <last_name>Simon Carson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>P3 Research Hawkes Bay</name>
      <address>
        <city>Havelock North</city>
        <zip>4130</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crawford Davidson</last_name>
      <phone>+64 6824 3070</phone>
      <email>CrawfordD@p3research.co.nz</email>
    </contact>
    <investigator>
      <last_name>Andrew McMaster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>P3 Research Tauranga</name>
      <address>
        <city>Tauranga</city>
        <zip>3110</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jo Swindail</last_name>
      <phone>+64 7 5970 453</phone>
      <email>joannes@p3research.co.nz</email>
    </contact>
    <investigator>
      <last_name>Jackie Kamerbeek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>P3 Research Wellington</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Timmings</last_name>
      <phone>+64 4801 0002</phone>
      <email>heather@p3research.co.nz</email>
    </contact>
    <investigator>
      <last_name>Joanna Joseph</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>February 3, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

